Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

An experimental therapy for Parkinson's disease being developed by ... and also after another alpha-synuclein drug tested in the disease – Biogen's cinpanemab – was abandoned in 2021 after ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

A phase 2 trial of Lundbeck’s alpha-synuclein ... other diseases including Parkinson’s, and is somewhat analogous to amyloid and tau proteins in Alzheimer’s disease.

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

“Parkinson’s is a progressive disease. It’s not something you can stabilize. It affects different parts of the body and it’s affected his legs,” she added. “But his voice is as good as ...

Jan. 21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms that resemble Parkinson's disease. The vitamin improves dopamine production in the brain and offers ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Other treatment areas in the corneal disease market include epithelial ... I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company ...